Shanghai Pharmaceuticals Holding Co., Ltd. (601607)

Equity Research Report　|　Industry: Pharmaceutical Distribution/Pharmaceutical Commercial　|　Report Date: September 13, 2026　|　Unless otherwise noted, all prices and indicator data are as of the September 11, 2026 close (certain fund/shareholder data are based on earlier dates, including September 10, 2026, August 28, 2026, and June 30, 2026; see the notes for each item)

This report was automatically compiled by AI based on publicly available information and is for reference only. It does not constitute investment advice.

1. Executive Summary

The core characteristics of Shanghai Pharmaceuticals are “large commercial scale, high industrial profit margins, and overall earnings affected by non-recurring factors”: revenue in 1H26 reached RMB 147.470 billion, up 4.15% year on year, while net profit attributable to shareholders was RMB 3.504 billion, down 21.40%; however, recurring net profit attributable to shareholders was RMB 2.477 billion, up 17.98%. This indicates that the apparent decline in profit was mainly caused by a high base resulting from non-recurring special gains in the same period of the previous year, while the underlying operating quality actually improved. During the same period, pharmaceutical commercial revenue was RMB 134.283 billion, up 3.75%, and pharmaceutical industrial revenue was RMB 13.186 billion, up 8.44%.

Approximately 91% of the company’s revenue comes from pharmaceutical commercial operations. The distribution business has a gross margin of only 5.71%, whereas the pharmaceutical industrial business has a gross margin of 59.73%, creating a two-engine structure in which “commercial operations provide scale and cash flow, while industrial operations provide profit.” Operating cash flow was a net inflow of RMB 4.450 billion in 1H26, relatively strong among the four distribution leaders covered here. However, the industry remains subject to the impact of centralized procurement, medical-insurance cost controls, the two-invoice system, and hospital bargaining power. Distribution therefore remains a low-margin business, with profit improvement depending more on industrial product-mix upgrades, CSO, SPD, DTP, and other value-added services.

Net profit attributable to shareholders was RMB 5.725 billion in 2025, up 25.74% year on year, but this was mainly attributable to a one-off special gain of more than RMB 1.0 billion resulting from Shanghai Hutchison Pharmaceuticals changing from equity-method accounting to consolidated accounting. Excluding this item, 2025 net profit attributable to shareholders was approximately RMB 4.721 billion, down 5.56%, while recurring net profit attributable to shareholders was RMB 2.980 billion, down 26.68%. In January 2025, the company acquired an additional 10% stake in Shanghai Hutchison Pharmaceuticals for RMB 995 million, raising its ownership to 60%, and established a RMB 5.01 billion biopharmaceutical M&A fund. The industrial segment and external M&A may become future sources of growth, although the realization of earnings remains to be monitored.

As of September 11, 2026, the company’s share price was RMB 16.29, with a total market capitalization of approximately RMB 60.409 billion and a price-to-book ratio of approximately 0.77x, indicating that the stock was trading below book value. Static PE, TTM PE, and forward PE were approximately 10.55x, 12.66x, and 8.6x, respectively, reflecting differences in calculation bases. Technically, MA5, MA10, and MA20 were all above the current price and concentrated in the RMB 16.40–16.44 range. MACD formed a bearish crossover above the zero axis, while the average chip cost was approximately RMB 16.99. Together with net main-fund outflows of RMB 26.1516 million during the week, the stock showed signs of weak, low-level consolidation in the short term.

2. Company Overview

2.1 Basic Information

2.2 Core Businesses and Product Portfolio

• Pharmaceutical industrial operations: R&D, clinical development, pilot production, commercial manufacturing, and marketing of drugs, medical devices, and healthcare products; focused on six therapeutic areas: immunology, psychiatry and neurology, oncology, cardiovascular, digestive and metabolic diseases, and anti-infectives; owns brands including “Xinyi, Leishi, Longhu, Qingchunbao, Hu Qing Yu Tang, and Cangsong,” as well as six China Time-honored Brands; has established pharmaceutical production bases in 12 domestic provinces and municipalities and overseas; produces approximately 700 drug varieties and more than 20 dosage forms annually; production facilities in East China occupy more than 2.22 million square meters, with total floor area exceeding 770,000 square meters (source: summary of a Yongxing Securities in-depth report and the etnet 02607 company business profile)
• Pharmaceutical commercial operations: the company describes itself as “China’s second-largest pharmaceutical commercial enterprise” and “the largest domestic service provider for imported drugs, vaccines, and medical devices”; its commercial channels and retail network cover 25 provincial-level administrative regions nationwide; businesses include distribution, warehousing, logistics and supply-chain solutions, and retail pharmacies (self-operated and franchised); it has CSO contracted-promotion cooperation with domestic and international pharmaceutical companies including Bayer and Sanofi (the Sanofi strategic cooperation covers more than 20 products, with a contract value exceeding RMB 5.0 billion; CSO sales were approximately RMB 6.1 billion in the first three quarters of 2024, up 176.3%, covering 18 pharmaceutical companies)
• Recent strategic actions: in January 2025, acquired an additional 10% stake in Shanghai Hutchison Pharmaceuticals from Hutchmed for RMB 995 million, raising its ownership to 60%, thereby obtaining control and consolidating the company; the transaction brought Musk Heart and Danning Tablets into the consolidated portfolio; in January 2025, established a RMB 5.01 billion biopharmaceutical M&A fund with partners, with the group contributing RMB 1.0 billion for a 19.96% stake; in September 2025, acquired an additional 10% stake in Shanghai Shangshi Group Finance Co., Ltd. from controlling shareholder Shanghai Industrial Investment (Group) for RMB 143 million, raising its ownership to 40%

2.3 Position in the Upstream and Downstream Value Chain and Cost/Profit Structure

Shanghai Pharmaceuticals is an integrated pharmaceutical company spanning industrial and commercial operations. Pharmaceutical commercial operations (distribution/retail) contribute approximately 91% of revenue but have very thin margins, while pharmaceutical industrial operations contribute approximately 9% of revenue but have high margins. Their contributions to profit are relatively similar, with industrial operations accounting for approximately 48% and distribution approximately 47%. Overall, the company exhibits the typical characteristics of a low-margin, midstream distribution business.

• Pharmaceutical commercial operations (approximately 91% of revenue): the true upstream consists of drug, device, and vaccine manufacturers, including many multinational pharmaceutical companies. As China’s largest service provider for imported drugs, vaccines, and medical devices, the company serves as an important import agent and channel platform for MNCs in China. Procurement prices are mainly determined by manufacturers’ ex-factory/tender prices and import landed prices. Distributors have limited pricing power upstream and function as “price takers plus service providers.”
• Low supplier concentration: in FY2025, purchases from the five largest suppliers were RMB 23.085 billion, accounting for only 9.12% of total purchases (FY2024: RMB 25.104 billion, or 10.26%).
• Pharmaceutical industrial operations (approximately 9% of revenue): upstream inputs include APIs, Chinese medicinal materials, excipients and packaging materials, and energy and utilities. The 2021 annual report disclosed that “utility expenses” in the industrial segment were approximately RMB 360 million, accounting for approximately 3.4%–3.7% of industrial costs, indicating that industrial costs are mainly composed of materials such as APIs and Chinese medicinal materials. The company is likewise relatively passive regarding bulk raw-material costs.
• Major customers include medical institutions at all levels, including hospitals, retail pharmacies, partners, and patients. The customer base is highly diversified and does not depend on a single major customer.
• Customer concentration: in FY2025, the five largest customers accounted for total sales of RMB 15.814 billion, or only 5.58% of total sales (FY2024: RMB 13.863 billion, or 5.04%; FY2021: RMB 9.546 billion, or 4.42%). Sources: FY2025 data from China Securities Intelligent Finance, Chaguwang, and cs.com.cn; FY2024/FY2021 data from the company’s annual reports published on Sina Finance. The definitions are consistent with the annual reports and are considered relatively reliable.
• Structural bargaining relationships: downstream hospitals hold strong bargaining power under centralized procurement, medical-insurance cost controls, and the two-invoice system, while hospital payment cycles are long. Upstream manufacturers have rigid pricing, leaving distributors squeezed from both sides. Distributors can only earn thin margins through scale, turnover, and value-added services such as SPD, CSO, DTP, and supply-chain finance. This is the fundamental reason distribution gross margin is only approximately 5.7% and the company’s overall net margin is only approximately 2.5%.
• The FY2025, FY2024, and FY2021 annual reports all show a highly diversified customer base with no dependence on a single major customer. This is a typical working-capital-intensive distribution model: the company must pay manufacturers/upstream suppliers first and then sell to hospitals on credit. Cash-flow evidence supports this: 1H26 operating cash flow was a net inflow of RMB 4.450 billion, compared with net outflows of RMB 23.763 billion for Sinopharm and RMB 2.781 billion for Jointown. Shanghai Pharmaceuticals had the strongest performance among the four major distributors. The research notes did not provide more detailed data such as accounts-receivable turnover days or the ratio of accounts receivable to net profit; these data are unavailable.
• On the supplier side, purchases from the five largest suppliers in FY2025 were RMB 23.085 billion, accounting for 9.12% of total purchases (FY2024: RMB 25.104 billion, or 10.26%). On the customer side, the five largest customers accounted for RMB 15.814 billion of sales in FY2025, or 5.58% of total sales (FY2024: RMB 13.863 billion, or 5.04%; FY2021: RMB 9.546 billion, or 4.42%). The customer and supplier concentration data come from annual reports and sources including China Securities Intelligent Finance and Chaguwang, and are consistent with the annual-report definitions. Reliability is considered relatively high. Concentration figures are annual data; the latest company annual report should be regarded as authoritative.

Shanghai Pharmaceuticals is positioned in the middle of the smile curve, in pharmaceutical distribution and circulation. Its revenue scale is enormous, with approximately 91% coming from distribution, but its distribution gross margin is extremely thin at approximately 5.7% and its overall net margin is approximately 2.5%. It is a typical “midstream distribution, low-margin” business. The industrial segment accounts for approximately 9% of revenue but has a gross margin as high as approximately 59.73%, with a profit contribution close to that of distribution, at approximately 48% versus approximately 47%. It is the company’s second profit pillar. Further margin improvement will mainly depend on upgrades to the industrial product mix and the expansion of innovative drugs and Chinese medicines, including Musk Heart and Danning Tablets following the consolidation of Shanghai Hutchison Pharmaceuticals; higher unit value-added in commercial operations through SPD, CSO, DTP, and supply-chain finance; and cash-flow advantages from scale and turnover efficiency, rather than increased pricing power over upstream or downstream parties.

3. Financial Data and Valuation Analysis

3.1 Recent Operating Performance

The sharp YoY decline in 1H26 net profit attributable to shareholders was mainly due to a high base caused by non-recurring special gains in the same period of the previous year. Recurring net profit attributable to shareholders was RMB 2.477 billion in 1H26, up 17.98%, and RMB 1.239 billion in 2Q26, up 48.17%. The 1H26 gross margin was 11.03%, the debt-to-assets ratio was 61.46%, investment income was RMB 827 million, and finance expenses were RMB 695 million. By segment, pharmaceutical industrial revenue was RMB 13.186 billion, up 8.44%, with segment profit of RMB 1.343 billion, up 1.51%; pharmaceutical commercial revenue was RMB 134.283 billion, up 3.75%, with segment profit of RMB 1.794 billion, flat year on year. R&D investment was RMB 1.053 billion. The proposed 1H26 cash dividend was RMB 371 million before tax, equivalent to 10.58% of net profit attributable to shareholders for the period. The sharp increase in 2025 net profit attributable to shareholders was mainly due to the change in accounting treatment for Shanghai Hutchison Pharmaceuticals from the equity method to consolidation, which generated a one-off special gain of more than RMB 1.0 billion. Excluding this item, 2025 net profit attributable to shareholders was approximately RMB 4.721 billion, down 5.56%. Recurring net profit attributable to shareholders was RMB 2.980 billion, down 26.68%; net operating cash flow was RMB 6.154 billion, up 5.61%; basic EPS was RMB 1.54; and the proposed dividend was RMB 3.5 per 10 shares. Recurring net profit attributable to shareholders in 1H25 was RMB 2.100 billion, down 22.38%. EPS was RMB 1.0161 in 2023 and RMB 1.2276 in 2024 (basic EPS of RMB 1.23 disclosed in the annual report). Note also that net profit including non-controlling interests as reported by etnet was RMB 6.992 billion in 2022, RMB 5.167 billion in 2023, RMB 5.870 billion in 2024, and RMB 6.974 billion in 2025. These differ from the attributable-to-shareholders figures because of non-controlling interests and must not be mixed. Sources: Securities Star, China International Capital Corporation research (September 1, 2026), Eastmoney; China Securities Journal·中证网 (March 31, 2026), Eastmoney (March 31, 2026), Cinda Securities (April 14, 2026), China Galaxy Securities (April 2, 2026), Tonghuashun (March 31, 2026); National Business Daily (March 28, 2025), MarketScreener, the original 2024 annual report published by the SSE; and the 2025 interim report disclosed by the Hong Kong Stock Exchange (hkexnews, September 15, 2025).

In the latest period, 1H26 revenue rose 4.15% year on year to RMB 147.470 billion, but net profit attributable to shareholders fell 21.40% to RMB 3.504 billion, while 2Q26 net profit attributable to shareholders fell 33.24% to RMB 2.087 billion. The apparent decline in profit was mainly due to the high base created by non-recurring special gains in the same period of the previous year. On a recurring basis, performance improved substantially: recurring net profit attributable to shareholders rose 17.98% in 1H26 and 48.17% in 2Q26, indicating that underlying operating quality improved. The sharp divergence between 2025 net profit attributable to shareholders of RMB 5.725 billion, up 25.74% and a record high since listing, and recurring net profit attributable to shareholders of RMB 2.980 billion, down 26.68%, was rooted in the one-off gain from consolidating Hutchison Pharmaceuticals. Looking only at attributable net-profit growth would overstate operating improvement; recurring and adjusted figures should be used to assess earnings power. In terms of business mix, pharmaceutical distribution accounted for approximately 91% of 1H26 revenue, pharmaceutical industrial operations approximately 9%, and pharmaceutical retail approximately 3%, forming a two-engine model of “pharmaceutical distribution plus industrial operations.” Industrial revenue growth of 8.44% exceeded commercial growth of 3.75%. Note that 2026 annual net profit attributable to shareholders may continue to decline modestly year on year, with several institutions forecasting a decrease of approximately 2%–9%. Operating profit/revenue definitions and figures for net profit attributable to shareholders versus net profit including non-controlling interests also differ across sources and must not be mixed.

3.2 Earnings Forecasts

Combined-source basis: Tonghuashun profile (as of 2026-08-08; 11 institutions in total over the preceding six months, https://profile.10jqka.com.cn/601607/worth/); Eastmoney F10 consensus estimates (six-month average; at the time of web capture, approximately corresponding to April 2026 or earlier; sample size 3–6 institutions, less representative than Tonghuashun’s 11-institution basis, http://emweb.securities.eastmoney.com/ProfitForecast/index?code=SH601607). Named brokerage forecasts: China International Capital Corporation (2026-09-01) maintained 2026/2027 net profit attributable to shareholders at RMB 6.016 billion/RMB 6.387 billion; China Post Securities (2026-04-01/02) forecast 2026–2028 revenue of RMB 298.087/313.625/330.009 billion and attributable net profit of RMB 5.553/6.005/6.605 billion; China Galaxy Securities (2026-04-01) forecast 2026–2028 attributable net profit of RMB 5.472/6.015/6.702 billion (-4.4%/+9.9%/+11.4%); CITIC Securities (2026-04-03) forecast EPS of RMB 1.39/1.52/1.64 for 2026E/2027E/2028E and rated the stock Buy; Western Securities (2026-05-08) forecast 2026–2028 attributable net profit of RMB 5.275/5.672/6.141 billion (-7.8%/+7.5%/+8.3%) and rated the stock Buy; Ping An Securities (2025-11-03) forecast 2025–2027 attributable net profit of RMB 5.195/5.689/5.966 billion and rated the stock Outperform; China Securities Construction Investment (2025-11-11) forecast EPS of RMB 1.40/1.53 for 2026E/2027E and rated the stock Buy; an unnamed brokerage (reproduced by CFi.cn, 2026-04-02) forecast 2026–2028 revenue of RMB 297.976/314.832/334.403 billion, attributable net profit of RMB 5.231/5.614/6.137 billion, EPS of RMB 1.41/1.51/1.65, and rated the stock Buy; Shenwan Hongyuan (2025-06-26) forecast 2025/2026/2027 attributable net profit of RMB 5.301/6.236/7.117 billion and EPS of RMB 1.43/1.68/1.92. This earlier forecast is now relatively optimistic. Eastmoney’s consensus estimates also include book value per share of approximately RMB 21.59, RMB 22.85, and RMB 24.43 for 2026E, 2027E, and 2028E, respectively, and forecast ROE of approximately 6.9%, 7.1%, and 7.1%. Note: estimates for “2026E” vary significantly across sources, with EPS ranging from RMB 1.39 to RMB 1.70 and net profit from RMB 5.16 billion to RMB 6.31 billion. The main differences concern the high base created by non-recurring gains and the extent to which investment in innovative drugs and CSO weighs on profit. Most institutions expect 2026 attributable net profit to decline modestly year on year, followed by single-digit growth in 2027–2028. Some forecasts come from individual brokerages and several are relatively old reports, such as Shenwan Hongyuan in June 2025 and Ping An Securities in November 2025, and may not reflect changes in the 2025 annual report or 1H26 results. The brokerage and report date must be specified when citing them.

3.3 Valuation and Institutional Ratings

Current share price/market capitalization: total market capitalization was RMB 60.409 billion as of September 12, 2026, ranking 1/32 in the pharmaceutical commercial sector; A-share free-float market capitalization was approximately RMB 45.44 billion. Based on approximately 3.708 billion total shares, the implied share price was approximately RMB 16.3, consistent with the RMB 16.29 shown by Sohu Securities. Valuation: TTM PE approximately 12.66x; 2025A approximately 10.55x; 2026E approximately 11.07x; 2027E approximately 10.33x; 2028E approximately 9.53x; PS approximately 0.21x. PB: 2025 book value per share was RMB 20.4649, corresponding to PB of approximately 0.80x and supporting its classification as a below-book-value stock. Other indicators: 2025 ROE of 7.74%; PEG of approximately 4.71; enterprise value/recurring net profit of approximately 52.4x. Performance references: -1.81% over the past month, +4.54% over the past three months, -1.53% over the past six months, and -6.25% year to date. Uncertainties: 1) the share-price and PE dates are not fully aligned (the RMB 60.409 billion market capitalization and approximately RMB 16.29 share price are based on September 12, 2026; Eastmoney’s PE table may have been captured before mid-September. The implied share price is approximately RMB 16.3, so the figures are internally consistent, but users should recheck them by trading date); 2) 2025 attributable net profit growth of 25.74% and recurring net profit decline of 26.68% diverged sharply, so earnings should be assessed using recurring or adjusted figures; 3) revenue figures for 2024 differ slightly across sources because of rounding, while “net profit” including non-controlling interests differs materially from attributable net profit and must not be mixed; 4) consensus estimates vary widely, with 2026E EPS of RMB 1.39–1.70 and net profit of RMB 5.16–6.31 billion. Eastmoney’s six-month average is based on only 3–6 institutions and is less representative than Tonghuashun’s 11-institution sample; 5) some estimates come from individual brokerages and older reports and may not reflect the latest developments; 6) H-share target prices from Morgan Stanley, UBS, and Goldman Sachs (HKD 15.8, HKD 15.2, and HKD 10.3) apply to 02607.HK and cannot be directly applied to A-share 601607. Goldman Sachs’ Sell rating also differs directionally from the Buy ratings of most A-share brokerages; 7) real-time market prices were not independently verified in this section, so PE/PB should be recalculated using the latest closing price. Sources: Securities Star weekly review (September 12, 2026), Eastmoney industry analysis, Eastmoney F10 ProfitForecast, CICC research, Gelonghui/Securities Star/NetEase reproductions (April 2026).

4. Recent News and Announcements

4.1 Controlling Shareholder Completes H-Share Purchase Plan

Controlling shareholder Shanghai Industrial Investment, based on its confidence in the company’s future development, announced a plan beginning September 15, 2025 to acquire H shares through its wholly owned subsidiary SIIC International Investment Co., Ltd. via centralized trading on the Hong Kong Stock Exchange within 12 months. The purchases would not exceed 2% of the voting shares (announcement Lin 2025-083). Progress was disclosed twice on May 8, 2026 (Lin 2026-036) and June 13, 2026 (Lin 2026-043). The July 2, 2026 announcement (Lin 2026-049) stated that, as of June 29, 2026, the purchase plan had been completed. A total of 74,000,000 H shares had been acquired, representing approximately 8.052% of issued H shares (919,072,704 shares) and 1.995% of total shares. Before the purchases, SIIC International held 300,438,000 H shares, or 8.102%. After completion, Shanghai Industrial Investment and parties acting in concert held or controlled 1,500,255,837 shares, or approximately 40.456% of total shares, including 374,438,000 H shares, equivalent to 40.741% of H shares and 10.097% of total shares. No shares were sold during the purchase period.

4.2 Company Clarifies That the Purchases Were Not a Buyback and That There Is No Current A-Share Buyback Plan

In a response on the investor-interaction platform dated June 24, 2026, the company corrected an investor’s statement that the June 13 announcement had repurchased only H shares and not A shares. The June 13 announcement concerned the controlling shareholder Shanghai Industrial Investment increasing its holdings after crossing the 1% threshold, not a share repurchase. The company stated that it had no A-share buyback plan to disclose and that market-capitalization management would rely mainly on operating performance, increases by the controlling shareholder, and higher dividend frequency. The response also reflected that the share price was trading below book value at that time, according to the investor’s original wording.

4.3 Internal Equity Transfer Agreement Among Parties Acting in Concert

The September 24, 2025 Summary Equity Change Report stated that Shanghai SIIC Yangtze River Delta Ecological Development Co., Ltd. had transferred its 40% stake in Shanghai Pharmaceutical Group to Shanghai Industrial Investment (Group) Co., Ltd. under an equity transfer agreement. The consideration was RMB 6,721,514,800, approximately RMB 6.722 billion, based on December 31, 2024. Before the change, Shanghai SIIC Yangtze River Delta indirectly held 286,606,415.6 Shanghai Pharmaceuticals shares, or 7.729%; after the change, it held none. The announcement said the transaction represented a strategic adjustment by Shanghai SIIC Yangtze River Delta and was an internal transfer within the Shanghai Industrial Investment system, rather than a secondary-market disposal. The information disclosure obligor stated that it had no plan to increase or reduce its holdings over the following 12 months.

4.4 Major Shareholder Structure (as of 2025-12-31)

HKSCC NOMINEES LIMITED (H shares): 24.76%; Shanghai Pharmaceutical (Group) Co., Ltd.: 19.32%; Yunnan Baiyao Group Co., Ltd.: 17.95%; SIIC International Investment: 8.40% (subsequently increased to approximately 10.10%, see the purchase results); Shanghai Industrial Investment (Group): 5.98%. Yunnan Baiyao is an important strategic shareholder and has related-party transactions. etnet data were updated through February 7, 2026.

4.5 Dividends and Shareholder Returns

For 1H25, the company paid RMB 1.2 per 10 shares, with a record date of December 31, 2025 and ex-dividend/payment date of January 5, 2026. For FY2024, it paid RMB 2.9 per 10 shares, with a record date of July 17, 2025 and ex-dividend date of July 18, 2025. The 2025 annual profit-distribution plan (Lin 2026-024, disclosed with the 2025 annual report around March 31, 2026) proposed a dividend of RMB 3.50 per 10 shares before tax. Based on total shares of 3,708,361,809, the proposed cash dividend totaled RMB 1,297,926,633.15. Including the RMB 445,003,417.08 already paid for 1H25, total cash dividends for 2025 amounted to RMB 1,742,930,050.23, or 30.45% of 2025 net profit attributable to shareholders of RMB 5,724,557,508.41. No capitalization of capital reserves was planned. For the 2026 interim dividend, the implementation announcement disclosed on September 10, 2026 stated that RMB 0.10 per share, or RMB 1.0 per 10 shares, would be paid. Based on 3,708,361,809 total shares, total cash distribution was RMB 370,836,180.90, including RMB 278,928,910.50 for A shares. The record date was September 17, 2026 and the ex-dividend date was September 18, 2026. The dividend policy commits to distributing no less than 30% of the average distributable profit of the previous three years over each three-year period. The company paid interim dividends in both 2024 and 2025, and the 2026 interim dividend plan was approved by shareholders on June 25, 2026. The company stated that, in addition to increases by the controlling shareholder, it would enhance shareholder returns by increasing dividend frequency while ensuring that dividends over three years remain no lower than 30% of the average distributable profit of the previous three years.

4.6 Lincomycin Hydrochloride Injection Passes Generic-Drug Consistency Evaluation

On September 10, 2026, subsidiary Shanghai Hefeng Pharmaceutical’s lincomycin hydrochloride injection passed the generic-drug consistency evaluation (notice No. 2026B05944). Approximately RMB 1.97 million had been invested in R&D. According to IQVIA, procurement of this drug by hospitals in mainland China totaled RMB 21.68 million in 2025.

4.7 Termination of Cooperation Agreement for the X842 Project with Guizhou Sinuo Biotechnology

On December 5, 2025, the company terminated its Production, Sales and Development Cooperation Agreement with Guizhou Sinuo Biotechnology for the novel acid-reducing drug X842 project (announcement Lin 2025-110). Shanghai Xinyi had received the return of RMB 110 million in advance payments and development and registration milestone fees from the counterparty and would charge a 3% annualized fund-usage fee. The company stated that the termination would not have a material impact on its financial position or operations. The original agreement was signed on October 8, 2021.

4.8 Announcements Relating to Subsidiary Shanghai Pharma Dongying (Jiangsu) Pharmaceutical’s Minuo

December 5, 2025: The subsidiary Shanghai Pharma Dongying (Jiangsu) Pharmaceutical’s Minuo (the research notes are incomplete here; the specific drug name and relevant data are unavailable).

5. Share-Price Trend and Technical Analysis

5.1 Price Overview

5.2 Technical Indicators

601607 Shanghai Pharmaceuticals operates in pharmaceutical commercial and pharmaceutical distribution, combining pharmaceutical distribution and industrial operations. It is controlled by the Shanghai state-owned-assets system, with the State-owned Assets Supervision and Administration Commission of Shanghai Municipality as its ultimate controller. The stock closed at RMB 16.29 on September 11, 2026, down 0.12%, with a PB of approximately 0.77x, indicating below-book trading. Static PE was 10.55x, TTM PE 12.66x, and forward PE approximately 8.6x. The definitions differ materially, so the report should not use a single figure. Technically, MA5 at RMB 16.44, MA10 at RMB 16.43, and MA20 at RMB 16.40 were tightly clustered and all above the current price, creating short-term resistance. The bearish moving-average death triangle on August 21, the MACD bearish crossover above the zero axis on September 10, and the RSI death cross and decline below 50 on September 9 all pointed to weakness. The average chip cost of RMB 16.99 was above the current price, creating overhang from trapped positions. The stock fell 1.99% during the week of September 7–11, with small daily declines from September 9 through 11. Net main-fund outflow during the week was RMB 26.1516 million. Margin financing balance was RMB 760 million as of September 10, 2026, and net margin-financing outflow over the past three months was approximately RMB 86.52 million, indicating generally weak fund flows. The 52-week high and low differ substantially across sources and can only be described as a range. A-share free-float market capitalization of approximately RMB 45.4 billion makes it a mid-to-large-cap stock, but its turnover rate of only 0.31% and trading value of RMB 142 million indicate low day-to-day liquidity and a thin order book, consistent with descriptions of 19.73% institutional participation, light control, and retail-dominated trading. Overall, the stock shows weak short-term technical and fund-flow conditions, low valuation, and below-book trading, exhibiting “low-level weak consolidation while awaiting changes in trading volume and news flow.”

5.3 Short-Term Outlook (Next Week; Scenario Analysis for Reference Only)

⚠️ Risk warning: The following content is a subjective scenario analysis based on the September 11, 2026 closing data, historical prices, and technical indicators. It does not constitute investment advice or any instruction to buy, sell, or hold.

① Key Technical Levels

② Scenarios for the Coming Week (Subjective Weights, Not Statistical Probabilities)

• Range-bound consolidation (RMB 16.10–16.68) (relatively higher weight, approximately 60%, subjective judgment): Trigger conditions include narrow fluctuations between the moving-average cluster at RMB 16.40–16.44 and the September 11 low of RMB 16.20, trading value remaining within the recent normal range of RMB 90–150 million, turnover of 0.20%–0.33%, modest main-fund outflows offset by proprietary-trading inflows and outflows, and no new catalyst from the news flow. Under this scenario, the moving averages would remain tightly clustered, MACD would fluctuate around the zero axis, and directional selection would be postponed.
• Weak downside (RMB 15.60–16.10) (medium weight, subjective judgment): Trigger conditions include trading value failing to expand or continuing to shrink, continued weekly net main-fund outflows, or broad weakness in the pharmaceutical commercial sector. A valid break below first support at RMB 16.10–16.25 and confirmed loss of RMB 16.20 intraday could lead to the estimated RMB 15.60–16.00 zone. This zone lacks verified intermediate support and therefore has low confidence.
• Stronger rebound (RMB 16.68–17.00) (low weight, subjective judgment): Trigger conditions include a clear increase in daily trading value above the upper end of the recent normal range, a shift to net main-fund inflows, or broad strength in the pharmaceutical commercial sector or company-specific catalysts such as consistency evaluations or shareholder distributions. Only a valid move above RMB 16.68 and a breakout through the second resistance zone at RMB 16.75–17.00 would confirm that rebound potential has opened.

③ Fund-Flow and Liquidity Background

Liquidity background: A-share free-float market capitalization is approximately RMB 45.4 billion, making the stock mid-to-large cap, but the September 11 turnover rate was only 0.31% and trading value was RMB 142 million. Recent daily trading value has typically been RMB 90–150 million (RMB 93 million on September 9, approximately RMB 113 million on September 10, and RMB 142 million on September 11), with turnover of 0.20%–0.33%. Overall liquidity is low and the order book is thin, so large fund flows can easily cause slippage. This is consistent with Eastmoney’s description of 19.73% institutional participation and light control and Jiufang Wealth’s description of retail-dominated trading. Fund flows: on September 11, main funds recorded a net outflow of RMB 12.9775 million, equivalent to 9.16% of total trading value; proprietary trading funds recorded a net inflow of RMB 9.4375 million and retail investors a net inflow of RMB 3.5399 million. Weekly net main-fund outflow was RMB 26.1516 million. Jiufang Wealth stated that main-fund outflows accounted for -25.77% over the past 10 trading days, five-day cumulative DDX was -0.058, and large-account outflows totaled RMB 7.997 million over 10 days. The margin-financing balance was RMB 760 million as of September 10, 2026, up 1.17% sequentially and equivalent to 1.67% of free-float market capitalization. Net margin-financing outflow over the past three months was approximately RMB 86.52 million, and the securities-lending balance was RMB 3.0942 million. Regarding northbound funds, Jiufang Wealth stated that northbound funds had recorded inflows on seven of the past 10 trading days and had recorded inflows for five consecutive days. As of June 30, 2026, northbound holdings were 57.1312 million shares, up 42.78% from the previous quarter-end; this is lagged quarterly data and may have changed. Shareholder structure: the top-10 shareholder data were dated August 28, 2026 (SSE official website). The largest shareholder, HKSCC NOMINEES LIMITED, held 918,271,749 shares, or 24.76%. HKSCC is the nominee/holding account of Hong Kong Securities Clearing Company and represents H-share and Stock Connect investors collectively, rather than a single actively managed institution. State-owned shareholders included Shanghai Industrial Investment (Group) at approximately 38.76%, Shanghai Pharmaceutical (Group) at approximately 19.32%, Jin Zhong International Holdings at 13.46%, and Shanghai Industrial Investment (Group) at 13.46%, according to askci’s consolidated figures. Limitation: this review precisely obtained information only on the first-ranked shareholder, HKSCC, and state-owned shareholders. It could not fully verify whether public funds, social-security funds, QFII, or other active institutions were among the top 10. The data are as of August 28, 2026, and the structure may have changed; the latest quarterly or interim report should be consulted. Disclosure lags may exceed one quarter, so current conditions may differ from the reported figures.

Observable volume-confirmation signal: If daily trading value remains above RMB 200 million, representing a clear expansion above the recent normal range of RMB 90–150 million, and this is accompanied by a shift in main funds from net outflow to net inflow, it may be viewed as a capital-involvement signal for assessing whether the rebound scenario has adequate volume support. Conversely, if trading value remains below RMB 100 million and main funds continue to flow out, the weak-downside or range-bound-consolidation scenario should receive relatively greater weight.

④ Key Points to Monitor (Observation Framework Only, Not Trading Instructions)

• Observation framework (not a trading instruction): Track the short-term resistance formed by the RMB 16.44–16.68 moving-average cluster and the September 7 high of RMB 16.68, as well as the effectiveness of first support at RMB 16.10–16.25 and strong support at RMB 15.00–15.05. After a break, monitor the downside or upside range that may open, including the alternative RMB 14.66 downside level after a break of strong support.
• Observation framework (not a trading instruction): Monitor whether the MACD lines stabilize around the zero axis and whether RSI can move back above 50 as supplementary indicators of a short-term trend transition. The current RSI value could not be verified and should be refreshed in real time.
• Observation framework (not a trading instruction): Whether trading value can expand above RMB 200 million and whether main funds can turn to net inflows are the core volume-confirmation signals for assessing the rebound scenario.
• Observation framework (not a trading instruction): Monitor the overall direction of the pharmaceutical commercial sector and company-specific news, such as consistency evaluations and implementation of interim shareholder distributions, as external triggers for scenario changes.

The above scenario analysis is based on closing data as of [2026-09-11] and calculations using historical prices and technical indicators. Short-term share prices may also be affected by news, fund flows, the broader market environment, and other factors. Technical indicators have inherent lags and limitations and do not guarantee future price movements or constitute buy or sell advice. Investors should independently assess the latest market information and bear investment risks themselves. The 52-week high and low, PE definitions, current RSI value, Bollinger Band values, and complete top-10 shareholder structure are subject to source discrepancies or missing data. See the notes above for details; these figures should not be used as a single definitive basis.

6. Industry Structure and Competitor Analysis

6.1 Industry Overview

China’s pharmaceutical distribution industry exhibits a “the strong get stronger” structure. The four major pharmaceutical distribution leaders—Sinopharm, Shanghai Pharmaceuticals, China Resources Pharmaceutical, and Jointown—hold a combined market share of more than 35%. Against the backdrop of centralized procurement, medical-insurance cost controls, the two-invoice system, and wholesale gross margins approaching their floor, distribution remains under pressure. Leading companies are seeking growth breakthroughs through retail, medical devices, CSO, and diversified services. Shanghai Pharmaceuticals describes itself as China’s second-largest pharmaceutical commercial enterprise and the country’s largest service provider for imported drugs, vaccines, and medical devices. It ranks 1/32 by market capitalization in the pharmaceutical commercial sector.

6.2 Competitive Landscape

• The four major pharmaceutical distribution leaders—Sinopharm, Shanghai Pharmaceuticals, China Resources Pharmaceutical, and Jointown—have a combined market share exceeding 35%. Industry concentration is high and the “strong get stronger” trend is evident (sources: Guangzhou Daily New Flower City, CLS).
• Wholesale gross margins are approaching their floor. The industry is restructuring from “wholesale” toward “services,” while the trillion-yuan pharmaceutical distribution market is seeking recovery through retail (source: Eastmoney).
• For the first time in 10 years, Sinopharm has slowed, while China Resources and Jointown have reported declining profits. The distribution “oligarchs” are undergoing internal “revolution” (source: finance.china.com).
• In the 1H26 comparison of the four major pharmaceutical commercial companies with annual revenue above RMB 100 billion, Shanghai Pharmaceuticals recorded a net operating cash inflow of RMB 4.450 billion, compared with net outflows of RMB 23.763 billion for Sinopharm and RMB 2.781 billion for Jointown. Shanghai Pharmaceuticals had the strongest cash-flow performance (source: xygpl.com).
• Major players are competing aggressively in medical devices, with Sinopharm, Shanghai Pharmaceuticals, China Resources, and Jointown all increasing investment in device distribution (source: Sohu).
• CSO/contract promotion has become an important incremental area of cooperation between pharmaceutical companies and distributors. Shanghai Pharmaceuticals’ strategic cooperation with Sanofi covers more than 20 products and has a contract value exceeding RMB 5.0 billion. CSO sales were approximately RMB 6.1 billion in the first three quarters of 2024, up 176.3%, covering 18 pharmaceutical companies.

6.3 Major Competitors

Compared with Sinopharm, China Resources Pharmaceutical, and Jointown, Shanghai Pharmaceuticals is an integrated industrial and commercial leader. Although industrial operations account for only approximately 9% of revenue, their gross margin is approximately 59.73% and their profit contribution is approximately 48%, creating a two-engine structure in which “commercial operations provide scale and cash flow, while industrial operations provide profit.” In 1H26, net operating cash inflow of RMB 4.450 billion was materially better than Sinopharm’s RMB 23.763 billion net outflow and Jointown’s RMB 2.781 billion net outflow, giving Shanghai Pharmaceuticals the strongest cash-flow performance among the four major distributors. However, its overall net margin is only approximately 2.5%, reflecting the same industry-wide pressure from floor-level distribution margins under centralized procurement, medical-insurance cost controls, and the two-invoice system. The research notes provide limited comparable data on peer gross margins, net margins, and customer/supplier concentration. This comparison is therefore based mainly on scattered information appearing in the research notes and does not make further assumptions.

7. Risk Factors

• Pharmaceutical commercial revenue accounts for approximately 91% of total revenue, but distribution gross margin is only 5.71%. Hospitals have strong bargaining power under centralized procurement, medical-insurance cost controls, and the two-invoice system, while upstream manufacturers’ prices are relatively rigid. The company faces sustained “two-sided squeeze” risk, and scale growth may not translate into parallel profit growth.
• The 25.74% increase in 2025 net profit attributable to shareholders was mainly due to the one-off special gain of more than RMB 1.0 billion generated by consolidating Shanghai Hutchison Pharmaceuticals rather than applying the equity method. Excluding this item, 2025 attributable net profit declined approximately 5.56% and recurring attributable net profit declined 26.68%. If underlying operating improvement falls short of expectations, the historically high growth rate may be difficult to sustain.
• The company is expanding its industrial and innovation footprint by increasing its stake in Shanghai Hutchison Pharmaceuticals and establishing a RMB 5.01 billion biopharmaceutical M&A fund. However, the integration of acquired targets, product ramp-up, and R&D investment remain uncertain. If project returns fall short of expectations, profit, cash-use efficiency, and goodwill-related assets may come under pressure.
• Although pharmaceutical industrial operations account for approximately 9% of revenue, they contribute close to half of profit. Earnings are therefore sensitive to a small number of high-margin products and the performance of the industrial segment. If new products, generic-drug consistency evaluations, or cooperation projects fail to generate effective sales, the thin-margin nature of the commercial segment may not be adequately offset by industrial profits.
• Net profit attributable to shareholders declined 21.40% year on year in 1H26. Although recurring attributable net profit rose 17.98%, profit, investment income, and special gains and losses remained volatile. Financial materials also differ in their treatment of attributable net profit and net profit including non-controlling interests. Mixing these definitions could overstate or understate sustainable earnings power.
• Customers and suppliers are relatively diversified, with the five largest customers accounting for 5.58% of sales and the five largest suppliers accounting for 9.12% of purchases. However, pharmaceutical distribution is inherently working-capital intensive. Hospital collection cycles, accounts-receivable balances, and working-capital usage may still affect cash flow. Current materials do not provide detailed indicators such as accounts-receivable turnover days, so the risk cannot be quantified further.
• As of September 11, 2026, the share price was below MA5, MA10, and MA20, with an average chip cost of approximately RMB 16.99 and weekly net main-fund outflows of RMB 26.1516 million. If volume remains low and fund outflows continue, the RMB 16.10–16.25 support area may come under pressure. Low liquidity may also magnify price volatility and trading slippage.
• The company has no A-share buyback plan. Current shareholder returns depend mainly on higher dividend frequency and the controlling shareholder’s purchases of H shares. If future profit growth, cash flow, or dividend capacity falls short of expectations, below-book trading and low valuation may not translate promptly into a valuation recovery.

8. Conclusion and Outlook

The company’s medium-term growth thesis is based mainly on three factors. First, pharmaceutical industrial revenue is growing faster than the commercial segment, and the consolidation of Shanghai Hutchison Pharmaceuticals can contribute Chinese-medicine products such as Musk Heart and Danning Tablets. Second, CSO, imported-drug and medical-device services, retail, and supply-chain value-added services may raise unit value-added in the commercial business. Third, the company’s operating cash-flow performance is strong, the controlling shareholder’s H-share purchase plan has been completed, and the 2026 interim distribution of RMB 0.10 per share maintains continuity in shareholder returns.

The quality of growth still needs to be validated through recurring profit and underlying operating performance. Market consensus estimates 2026 revenue of approximately RMB 300.6 billion and attributable net profit of approximately RMB 5.583 billion, implying a modest profit decline. Profit expectations for 2027–2028 are projected to recover to single-digit growth, but institutions differ considerably in their 2026 EPS and net-profit forecasts. Key items to monitor include industrial-segment profit growth, commercial gross margin and cash turnover, the actual contribution from CSO and M&A projects, and whether profit can continue to improve after the one-off gains fade.

The company’s valuation is low, but this low valuation also reflects the pharmaceutical distribution industry’s low margins, limited bargaining power in commercial operations, and near-term earnings volatility. Technical indicators and fund flows are currently weak, and the company has explicitly stated that it has no A-share buyback plan. Whether fundamental improvement and valuation recovery can reinforce each other will therefore depend on the realization of underlying earnings, market risk appetite toward the pharmaceutical commercial sector, and improvement in trading volume.

Data Sources

• 601607 Shanghai Pharmaceuticals
• Shanghai Pharmaceuticals (601607)_Company Overview_Share Price_Real-Time Market Data_Chart_News_Analyst Commentary_Financial Reports_FinScope-AI Makes Investing Simpler
• 601606 Great Wall Military Industry
• Great Wall Military Industry (601606.SH) Core Topics-PC_HSF10 Data - Core Topics
• Great Wall Military Industry (601606)
• Great Wall Military Industry (601606)_Company Profile_CFi.cn
• Shanghai Pharmaceuticals (601607) Weekly Review: Down 1.99% This Week, Net Main-Fund Outflow of RMB 26.1516 Million
• Shanghai Pharmaceuticals Group Co., Ltd. (a joint-stock company incorporated in the People’s Republic of China) (H-share code: 02607) (A-share code: 601607)
• Shanghai Pharmaceuticals: 16.29 -0.12% -0.02 601607 Sohu Securities
• Shanghai Pharmaceuticals (601607) September 11 Main-Fund Net Sales of RMB 12.9775 Million
• 601607 Shanghai Pharmaceuticals - Main Business
• Shanghai Pharmaceuticals (601607) 1H26 Management Discussion and Analysis-Securities Star
• Company A-Share Code: 601607
• Shanghai Pharmaceuticals (601607.SH) Operating Analysis-PC_HSF10 Data - Main Business
• 02607 Shanghai Pharmaceuticals SH PHARMA - Free Real-Time Stock Quote - Company Business
• Shanghai Pharmaceuticals (601607)_Operating Summary_CFi.cn
• Shanghai Pharmaceuticals (601607)_Operating Summary_CFi.cn
• First Institutional Coverage-Research Reports-Stock Channel-Securities Star
• Shanghai Pharmaceuticals 2024 Annual Report: Accelerating the Construction of an Innovation Ecosystem and Achieving Breakthroughs Through Industrial-Commercial Synergy
• The Strong Get Stronger? Four Major Pharmaceutical Distribution Leaders Capture More Than 35% of Market Share
• 2025 China Pharmaceutical Distribution Industry Competitive Landscape and Rankings
• Analysis of First-Quarter Highlights from Sinopharm, Shanghai Pharmaceuticals, China Resources Pharmaceutical, Jointown, and Other Leading Commercial Companies
• Four Major Pharmaceutical Companies’ 2025 Interim Reports: Distribution Under Pressure and Seeking Breakthroughs Through Retail and Diversified Growth
• Sinopharm, Shanghai Pharmaceuticals, China Resources, and Jointown: Device Capabilities Compared
• Sinopharm, Shanghai Pharmaceuticals, China Resources, and Jointown: Medical-Device Capabilities Compared
• Wholesale Gross Margins at the Floor; Service Restructuring as a Breakthrough: Can Trillion-Yuan Pharmaceutical Distribution Recover Through Retail?
• First Time in 10 Years! Sinopharm Slows, China Resources and Jointown Profits Decline, and Distribution “Oligarchs” Begin Self-Revolution
• 1H26 Comparison of the Four Major Pharmaceutical Commercial Companies with Revenue Above RMB 100 Billion
• Wholesale Gross Margins at the Floor; Service Restructuring as a Breakthrough: Can Trillion-Yuan Pharmaceutical Distribution Recover Through Retail?
• Shanghai Pharmaceuticals (601607)_Company Announcement_Shanghai Stock Exchange Inquiry Response to the 2025 Annual Report
• Deloitte Huayong Response to the Shanghai Stock Exchange’s Information-Disclosure Regulatory Inquiry on Shanghai Pharmaceuticals’ 2025 Annual Report
• Shanghai Pharmaceuticals: Response Announcement to the Shanghai Stock Exchange’s Inquiry on the 2025 Annual Report_Jiufang Wealth
• Shanghai Pharmaceuticals: 2025 Net Profit of RMB 5.725 Billion, Up 25.74%; Proposed Dividend of RMB 3.5 per 10 Shares
• Deloitte Huayong Response to the Shanghai Stock Exchange’s Information-Disclosure Regulatory Inquiry on Shanghai Pharmaceuticals’ 2025 Annual Report
• Shanghai Pharmaceuticals (601607) Main-Business Operating Analysis_Chaguwang
• Shanghai Pharmaceuticals - Industrial | Utility Expenses
• Shanghai Pharmaceuticals Company Announcement: Deloitte Huayong Response to the 2025 Annual Report Inquiry
• Shanghai Pharmaceuticals: Deloitte Huayong Response to the 2025 Annual Report Inquiry_Jiufang Wealth
• Shanghai Pharmaceuticals: 2021 Annual Report (Revised Version)
• Shanghai Pharmaceuticals Financial Summary
• Shanghai Pharmaceuticals (601607) Income Statement_Investing.com
• Bank of Communications - Company Information
• Shanghai Pharmaceuticals Holding (SHA:601607) Income Statement
• SH.601607 Shanghai Pharmaceuticals SHANGHAI PHARM - A-Share Real-Time Quote - Company Information
• Shanghai Pharmaceuticals (601607): Operating Performance Meets Expectations; Looking Forward to Steady Growth in the Core Business
• Shanghai Pharmaceuticals: 2025 Net Profit of RMB 5.725 Billion, Up 25.74%; Proposed Dividend of RMB 3.5 per 10 Shares
• Strengthening and Upgrading Core Businesses; Focus on Industrial Marketing Transformation and Innovation
• Shanghai Pharmaceuticals (601607) 2025 Annual Results Review: Steady Revenue Growth and Future Growth Driven by Organic and External Expansion
• Shanghai Pharmaceuticals 2025 Annual Results Review: Steady Revenue Growth, Future Growth Driven by Organic and External Expansion-Securities Star
• 2025 Annual Results Review: Industrial Transformation, Cost Reduction and Efficiency Improvement; Multiple Breakthroughs in Commercial Innovation
• Shanghai Pharmaceuticals (601607) 2025 Annual Report Briefing: Revenue and Net Profit Both Increased Year on Year
• Shanghai Pharmaceuticals (601607): Innovative-Drug Business Expands Rapidly; Chinese-Medicine Industrial Operations Inject New Momentum
• Hutchison Consolidation Boosts Results; Shanghai Pharmaceuticals Net Profit Up 25.74%
• Major-Bank Rating | Morgan Stanley: Slightly Cuts Shanghai Pharmaceuticals Target Price to HKD 15.8, Maintains “Overweight”
• Major-Bank Rating | Morgan Stanley: Slightly Cuts Shanghai Pharmaceuticals Target Price to HKD 15.8, Maintains “Overweight”
• Major-Bank Rating | Morgan Stanley: Slightly Cuts Shanghai Pharmaceuticals Target Price to HKD 15.8, Maintains “Overweight”
• Major-Bank Rating | Goldman Sachs: Slightly Raises Shanghai Pharmaceuticals Target Price to HKD 10.3, Maintains “Sell”
• Major-Bank Rating | Goldman Sachs: Slightly Raises Shanghai Pharmaceuticals Target Price to HKD 10.3, Maintains “Sell”
• Major-Bank Rating | Morgan Stanley: Slightly Cuts Shanghai Pharmaceuticals Target Price to HKD 15.8, Maintains “Overweight”_Jiufang Wealth
• 601607 Shanghai Pharmaceuticals
• Major-Bank Rating | UBS: Raises Shanghai Pharmaceuticals Target Price to HKD 15.2, Maintains “Buy”
• 601607 Shanghai Pharmaceuticals
• http://finance.sina.com.cn/stock/bxjj/2026-04-24/doc-inhvqmqh4767591.shtml.md
• Hong Kong Stock Individual-Stock Investment Forecast Composite Value - Shanghai Pharmaceuticals - 2025 - Tonghuashun
• Shanghai Pharmaceuticals (601607) Value Analysis_Stock Market Data_Tonghuashun
• Research Report Table - Shenwan Hongyuan - June 26, 2025 - Tonghuashun
• Shanghai Pharmaceuticals (601607): Results Meet Expectations; Innovative Business Maintains Strong Growth
• Shanghai Pharmaceuticals (601607): Innovative-Drug Business Continues to Advance; Pharmaceutical Commercial Operations Grow Steadily
• Shanghai Pharmaceuticals (601607): Net Profit Exceeds Expectations; Industrial Segment Improves Quality and Efficiency
• Shanghai Pharmaceuticals (601607.SS) Analyst Ratings, Estimates and Forecasts - Yahoo Finance
• 601607 Shanghai Pharmaceuticals
• Shanghai Pharmaceuticals (601607)
• Shanghai Pharmaceuticals (601607) Operating Analysis_Tonghuashun
• SH.601607 Shanghai Pharmaceuticals SHANGHAI PHARM - A-Share Real-Time Quote - Company Information
• Shanghai Pharmaceuticals (601607) - F10 Data - Compass Market Data
• Shanghai Pharmaceuticals: 601607_2025 Annual Report Full Text-Jiufang Wealth
• Shanghai Pharmaceuticals: 601607_2025 Annual Report Full Text-Jiufang Wealth
• 601607 Shanghai Pharmaceuticals
• Shanghai Pharmaceuticals (601607.SH): Famotidine Injection Passes Generic-Drug Consistency Evaluation
• Shanghai Pharmaceuticals (601607): Termination of Cooperation Agreement with Guizhou Sinuo Biotechnology
• Shanghai Pharmaceuticals Group Co., Ltd. Summary Equity Change Report
• Shanghai Pharmaceuticals: Resolution of the 27th Meeting of the Eighth Board of Directors_Jiufang Wealth
• Shanghai Pharmaceuticals (601607.SH): Omeprazole/Sodium Bicarbonate Dry Suspension (II) Approved for Production
• Shanghai Pharmaceuticals: 2025 Annual Profit Distribution Plan_Jiufang Wealth
• Shanghai Pharmaceuticals Group Co., Ltd. Announcement on Termination of Cooperation Agreement with Guizhou Sinuo Biotechnology - 2025
• Shanghai Pharmaceuticals: Lincomycin Hydrochloride Injection Passes Generic-Drug Consistency Evaluation_Jiufang Wealth
• X842 Project Terminated: Shanghai Pharmaceuticals Ends Cooperation Agreement with Guizhou Sinuo Biotechnology-Securities Star
• Shanghai Pharmaceuticals: Lincomycin Hydrochloride Injection Passes Consistency Evaluation, RMB 1.97 Million
• Shanghai Pharmaceuticals (601607.SH): Lincomycin Hydrochloride Injection Passes Generic-Drug Consistency Evaluation
• Shanghai Pharmaceuticals (601607.SH) 2026 Interim Distribution: RMB 0.10 per Share
• Shanghai Pharmaceuticals: Hefeng’s Lincomycin Hydrochloride Injection Passes Generic-Drug Consistency Evaluation
• Shanghai Pharmaceuticals: Lincomycin Hydrochloride Injection Passes Consistency Evaluation, RMB 1.97 Million-Securities Star
• Shanghai Pharmaceuticals (601607.SH) Subsidiary’s Lincomycin Hydrochloride Injection Passes Generic-Drug Consistency Evaluation
• Shanghai Pharmaceuticals (601607.SH) 2026 Interim Distribution: RMB 0.10 per Share
• Shanghai Pharmaceuticals: Announcement on Lincomycin Hydrochloride Injection Passing Generic-Drug Consistency Evaluation
• Shanghai Pharmaceuticals: Lincomycin Hydrochloride Injection Passes Generic-Drug Consistency Evaluation
• Shanghai Pharmaceuticals: Lincomycin Hydrochloride Injection Passes Generic-Drug Consistency Evaluation
• Shanghai Pharmaceuticals (02607.HK) 3Q Net Profit RMB 5.147 Billion, Up 27%
• Shanghai Pharmaceuticals (601607)_Profit Distribution Statement_CFi.cn
• Shanghai Pharmaceuticals (601607) Income Statement and Main-Business Profit_Securities Star
• Shanghai Pharm Results - Investing.com
• Shanghai Pharmaceuticals (02607.HK) 3Q Net Profit RMB 3.797 Billion, Down 21.13%
• Shanghai Pharmaceuticals Earnings - Investing.com
• Shanghai Pharmaceuticals Holding (SHA:601607) Stock Price & Overview
• Shanghai Pharmaceuticals Holding Co Ltd Earnings Dates and Estimates - RTTNews.com
• https://finance.sina.com.cn/stock/zqgd/2026-09-10/doc-inirixkn8588062.shtml.md
• China Investor Relations Platform Interactive Q&A - Shanghai Pharmaceuticals Group Co., Ltd. - June 23, 2026 - Tonghuashun
• Shanghai Pharmaceuticals: Market-Capitalization Management Is a Long-Term Strategy; Multiple Measures Strengthen Market Communication and Focus on Shareholder Returns
• Shanghai Pharmaceuticals: June 2026 Investor Relations Activity Record
• Shanghai Pharmaceuticals: In Addition to Increases by the Controlling Shareholder, the Company Will Increase Dividend Frequency to Enhance Shareholder Returns
• Super Intelligent Agent
• Overseas Regulatory Announcement_Shanghai Pharmaceuticals (02607)_Announcement
• Shanghai Pharmaceuticals 1Q26 Results Presentation
• Shanghai Pharmaceuticals Group Co., Ltd. Investor Relations Activity Record - June 2026
• Shanghai Pharmaceuticals Conversion - Company Stock: Shanghai Pharmaceuticals
• Shanghai Stock Exchange Company Announcements - Shanghai Pharmaceuticals: Completion of the Controlling Shareholder’s Purchase Plan and Results
• Shanghai Pharmaceuticals (601607.SH): Lincomycin Hydrochloride Injection Passes Generic-Drug Consistency Evaluation
• Shanghai Pharmaceuticals Group Co., Ltd. 2026 Interim Distribution Implementation Announcement
• Shanghai Pharmaceuticals Group Co., Ltd. 601607
• China Securities Journal - Shanghai Pharmaceuticals Group Co., Ltd. 2026 Interim Distribution Implementation Announcement
• Shanghai Pharmaceuticals (sh601607)
• e Company, the First Information Platform for Listed Companies
• Shanghai Pharmaceuticals (601607)_Company Overview_Share Price_Real-Time Market Data_Chart_News_Analyst Commentary_Financial Reports_FinScope-AI Makes Investing Simpler
• Shanghai Pharmaceuticals 16.29 -0.02 (-0.12%) Latest Price_Market Data_Chart—Eastmoney
• Shanghai Pharmaceuticals (sh601607) Market Trend
• Shanghai Pharmaceuticals: Lincomycin Hydrochloride Injection Passes Generic-Drug Consistency Evaluation
• Shanghai Pharmaceuticals (601607) Latest Price_Market Data_Chart-Mobile Eastmoney
• Weekly Review (September 7–11): Shanghai Pharmaceuticals Down 1.99%, Net Main-Fund Outflow of RMB 26.1516 Million-Securities Star
• Shanghai Pharmaceuticals (sh601607) Market Trend - September 9, 2026 15:18:50 Beijing Time
• Shanghai Pharmaceuticals (601607)_Company Overview_Share Price_Real-Time Market Data_Chart_News_Analyst Commentary_Financial Reports_FinScope-AI Makes Investing Simpler
• Shanghai Pharmaceuticals (sh601607) Stock Price_Real-Time Market Data_Chart-Sina Finance
• Shanghai Pharmaceuticals (02607) Stock Price, Real-Time Market Data, News and Financials-Sina Finance
• Shanghai Pharmaceuticals (SH:601607)
• Shanghai Pharmaceuticals (SH:601607) - Shanghai Pharmaceuticals
• Download 601607 Data | Shanghai Pharmaceuticals Holding Co. Ltd. Price Data | MarketWatch
• Shanghai Pharmaceuticals (601607) Share Price and News - Finance
• Shanghai Pharmaceuticals (601607.SH) - U.S. Stocks
• Shanghai Pharmaceuticals Holding Co Ltd (601607) Stock Forums - Investing.com Canada
• Shanghai Pharmaceuticals Holding (SHSE:601607) - Stock Analysis - Simply Wall St - NOT FOR DISTRIBUTION
• Shanghai Pharmaceuticals (601607)_Latest Price_Market Data_Chart—Eastmoney
• Shanghai Pharmaceuticals (601607) Stock Commentary_Eastmoney Data Center
• Shanghai Pharmaceuticals Holding Co Ltd Stock Technical Analysis (601607) - Investing.com ZA
• Shanghai Pharmaceuticals (601607) Technical Analysis - Shanghai Pharmaceuticals
• A-Share Real-Time Quote - Interactive Chart
• Advanced Chart 601607 | Shanghai Pharm - Investing.com
• Technical Analysis of Shanghai Pharmaceuticals Holding Co. Ltd. Class A (SSE:601607) — TradingView — India
• Shanghai Pharmaceuticals (601607) Market Data_Chart_Jiufang Wealth
• Shanghai Pharmaceuticals Holding Co., Ltd: Technical Analysis Chart | 601607 | CNE000000C82 | MarketScreener
• 601607 - Shanghai Pharmaceuticals Holding Co., Ltd - Chart Tool
• Shanghai Pharmaceuticals (601607) Fund Flows_Eastmoney Data Center
• Shanghai Pharmaceuticals (601607.SH)
• Shanghai Pharmaceuticals 16.48 -0.54%_Stock Market Data_Jiufang Wealth
• Shanghai Pharmaceuticals (601607.SH) - Quick Quote

This report was automatically retrieved, compiled, and generated by AI based on publicly available information. Unless otherwise noted, all prices and indicator data are as of the September 11, 2026 close (certain fund/shareholder data are based on earlier dates, including September 10, 2026, August 28, 2026, and June 30, 2026; see the notes for each item). The information may differ in timeliness. Specific data should be verified against the company’s formal announcements and authoritative data terminals. This report is for information and research reference only and does not constitute investment advice. Investors should make independent judgments and bear investment risks themselves.